DiaSys' immunoassay developer Thomas Masetto was invited to speak at the Stakeholder Event of the EU-funded (EMPIR) project SEPTIMET and at a EURAMET workshop.
SEPTIMET Stakeholder Event - September 14, 2021
The SEPTIMET project is dedicated to improve the time to result, accuracy and reproducibility of diagnostic tests for the detection and treatment of sepsis.
The aims of this clinically oriented project are:
- Improve the accuracy of established biomarkers used to identify sepsis patients
- Develop a metrological framework for current methods used to guide treatment of sepsis
- Reference methods for rapid near patient (Point of care) testing for sepsis
- Describe performance and measurement needs of new methods for early sepsis diagnosis
- Ficilitat measurement infrastructure uptake by hospitals, industry and standard providers
Mr. Masetto's presentation highlighted challenges an IVD manufacturer faces when developing IVD kits for sepsis marker measurement. He also explained the advantages and disadvantages of CLIA and PETIA technology, the impact of antibodies on the performance of various Procalcitonin assays, and the standardization of calibrators.
Those interested in learning more about the SEPTIMET project and expanding their knowledge of sepsis have the opportunity to view the full recording of the event on YouTube. The DiaSys presentation starts at 1:06:03: https://youtu.be/kjD8GnRyEIk